Type I Interferon Inhibition for SLE Cardiometabolic Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with type I IFN mediated diseases, such as systemic lupus erythematosus (SLE), experience premature cardiovascular disease due to unexplained atherosclerosis and vascular damage, with current treatments having adverse effects and limited efficacy, and advanced imaging modalities for CVD risk assessment are not accessible to all.
Innovation Solution
Administering a therapeutically effective amount of an inhibitor of type I IFN signalling, such as anifrolumab, to patients with type I IFN mediated diseases to reduce markers of cardiometabolic disease, including GlycA, neutrophil extracellular trap (NET), TNF-α, and IL-10, thereby treating cardiovascular disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cardiometabolic risk factors and immunosuppressive treatments are used, then cardiovascular risk is managed, but they cannot fully account for enhanced CVD in SLE patients and have well-documented safety issues
Solution Approach 1:
The patent extracts and targets the specific pathogenic mechanism of type I interferon signaling in SLE patients, separating it from general immunosuppression. By using monoclonal antibodies (anifrolumab, satralizumab) that specifically block type I interferon receptors, the treatment addresses the root cause of accelerated atherosclerosis without the broad immunosuppressive effects that cause adverse events like infection and malignancy
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific immunosuppression to specific type I interferon pathway inhibition. This parameter change allows for targeted blockade of the interferon-alpha/beta signaling pathway that drives vascular inflammation and atherosclerosis, while preserving other immune functions, thereby improving the efficacy-safety profile
2Ease of operation
If corticosteroids are used to control disease activity, then disease symptoms are managed, but long-term use causes increased cardiovascular mortality and side effects
Solution Approach 1:
The patent introduces type I interferon pathway inhibition as an intermediary mechanism to achieve disease control without corticosteroids. The monoclonal antibodies act as intermediaries that block the upstream interferon signaling pathway, thereby reducing downstream inflammatory cascades and tissue damage that currently require corticosteroid intervention
Solution Approach 2:
The patent applies preliminary action by blocking type I interferon signaling before it can trigger the inflammatory cascade that leads to corticosteroid dependence. By preemptively inhibiting the interferon pathway, the treatment prevents the development of severe flares that would require high-dose corticosteroids, thereby avoiding their long-term adverse effects
3Measurement precision
If advanced imaging modalities are used for CVD risk assessment, then accurate risk markers are obtained, but they are not accessible to all patients
Solution Approach 1:
The patent employs biomarkers such as GlycA (measured by NMR spectroscopy) and cholesterol efflux capacity that can be assessed through relatively simple, cost-effective blood tests compared to advanced imaging modalities like PET-CT. These biomarkers provide accurate CVD risk assessment without requiring expensive, specialized equipment, thereby improving accessibility
Solution Approach 2:
The patent replaces complex mechanical imaging systems (PET-CT, MRI) with biochemical measurement systems that detect molecular biomarkers in blood. This substitution maintains measurement precision for CVD risk assessment while dramatically improving accessibility, as blood tests can be performed in routine clinical laboratories rather than specialized imaging centers
Data Source
AI summary
The disclosure relates to methods for the treatment of, or for reducing the risk for development of, a cardiometabolic in a patient using an inhibitor of type I IFN signalling.